CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-27

Gut microbiota, innate immunity and endocannabinoid system interactions link metabolic inflammation with the hallmarks of obesity and type 2 diabetes

Ziel

Obesity and type 2 diabetes are characterized by metabolic inflammation and an altered endocannabinoid system (eCB) tone. We have provided evidence that gut microbiota modulate both intestinal and adipose tissue eCB system tone. Insulin resistance and inflammation have been linked to microbiota-host interaction via different Toll-Like Receptors (TLR’s). Our preliminary data show that tamoxifen-induced epithelial intestinal cells deletion of the key signalling adaptor MyD88 (myeloid differentiation primary-response gene 88), that encompass most of the TLR’s, protect mice against diet-induced obesity and inflammation. A phenomenon closely linked with changes in the intestinal eCB system tone and antimicrobial peptides production. Moreover, we discovered that the recently identified bacteria living in the mucus layer, namely Akkermansia muciniphila, plays a central role in the regulation of host energy metabolism by putative mechanisms linking both the intestinal eCB system and the innate immune system. Thus these preliminary data support the existence of unidentified mechanisms linking the innate immune system, the gut microbiota and host metabolism. In this high-risk/high-gain research program, we propose to elucidate what could be one of the most fundamental processes shared by different key hallmarks of obesity and related diseases. A careful and thorough analysis of the molecular and cellular events linking gut microbiota, the innate immune system and eCB system in specific organs has the potential to unravel new therapeutic targets. We anticipate the key role of MyD88 and the enzyme NAPE-PLD (N-acylphosphatidylethanolamine phospholipase-D) involved in the synthesis of N-acylethanolamines family to be key determinant in such pathophysiological aspects. Thus, these approaches could provide different perspectives about disease pathogenesis and knowledge-based evidence of new therapeutic options for obesity and associated metabolic disorders in the future.

Aufforderung zur Vorschlagseinreichung

ERC-2013-StG
Andere Projekte für diesen Aufruf anzeigen

Gastgebende Einrichtung

UNIVERSITE CATHOLIQUE DE LOUVAIN
EU-Beitrag
€ 1 494 640,00
Adresse
PLACE DE L UNIVERSITE 1
1348 Louvain La Neuve
Belgien

Auf der Karte ansehen

Region
Région wallonne Prov. Brabant Wallon Arr. Nivelles
Aktivitätstyp
Higher or Secondary Education Establishments
Hauptforscher
Patrice Daniel Cani (Prof.)
Kontakt Verwaltung
Anne Bovy (Mrs.)
Links
Gesamtkosten
Keine Daten

Begünstigte (1)